FY2025 · ended Dec 31, 2025 · Revenue $134.48M, -3.9% YoY · Filed Feb 25, 2026
RxSight, Inc. (RXST) files with the SEC under industry code 3851, Ophthalmic Goods. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $134.5 million and a net loss of $38.9 million. Free cash flow was -$19.3 million. As of Sep 30, 2026 it held $254.7 million in cash and investments and $10.3 million in total debt.
Revenue (TTM)
$115.29M
-18.9% vs year-ago TTM
Net income (TTM)
$-53.36M
-49.3% vs year-ago TTM
Operating cash flow (TTM)
$23.67M
+226.9% vs year-ago TTM
Free cash flow (TTM)
$18.64M
+184.0% vs year-ago TTM
EPS (TTM)
$-1.29
-46.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
41.27M
+1.9% vs prior year
Net cash
$244.36M
as of Sep 30, 2026
Operating margin
-53.3%
FY 2026
Company profile
- Industry
- Ophthalmic Goods (SIC 3851)
- Listed as
- RXST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Aliso Viejo, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1111485
- Former names
- CALHOUN VISION INC (until Mar 20, 2014)
Other Ophthalmic Goods companies
- Alcon Inc ALC
- Cooper Companies, Inc. COO
- Bausch & Lomb Corp BLCO
- Warby Parker Inc. WRBY
- National Vision Holdings, Inc. EYE
- Staar Surgical Co STAA
- Innovative Eyewear Inc LUCY
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $134.5M | $139.9M | $89.1M | $49.0M | $22.6M |
| Operating income | -$48.2M | -$36.9M | -$50.1M | -$63.3M | -$52.8M |
| Net income | -$38.9M | -$27.5M | -$48.6M | -$66.8M | -$48.7M |
| Diluted EPS | -$0.95 | -$0.71 | -$1.41 | -$2.41 | -$3.57 |
| Operating cash flow | -$15.5M | -$16.9M | -$41.6M | -$58.9M | -$44.7M |
| Free cash flow | -$19.3M | -$22.4M | -$46.4M | -$61.2M | -$46.6M |
| Total assets | $311.8M | $318.6M | $182.6M | $150.2M | $192.7M |
| Total liabilities | $36.1M | $37.3M | $22.2M | $60.3M | $54.5M |
| Stockholders' equity | $275.7M | $281.2M | $160.4M | $89.9M | $138.2M |
| Cash and investments | $228.1M | $237.2M | $127.2M | $105.8M | $159.3M |
| Total debt | $11.0M | $12.3M | $3.0M | $45.0M | $44.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 15, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 6, 2026 | Jun 30, 2026 |
All 474 RxSight, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.